Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
aTyr Pharma ( (ATYR) ) has provided an update.
On September 15, 2025, aTyr Pharma announced the topline results from its Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis. The study did not meet its primary endpoint of reducing the mean daily oral corticosteroid dose, but showed clinical improvement in the King’s Sarcoidosis Questionnaire-Lung score and maintained lung function. The company plans to engage with the FDA to discuss the results and determine the next steps for efzofitimod’s development, highlighting its potential activity across multiple efficacy endpoints.
The most recent analyst rating on (ATYR) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on aTyr Pharma stock, see the ATYR Stock Forecast page.
Spark’s Take on ATYR Stock
According to Spark, TipRanks’ AI Analyst, ATYR is a Neutral.
aTyr Pharma’s stock score is primarily impacted by its financial challenges, including negative profitability and cash flow issues. While technical indicators show positive momentum, the poor valuation due to negative earnings and lack of dividends weighs heavily on the overall score.
To see Spark’s full report on ATYR stock, click here.
More about aTyr Pharma
aTyr Pharma, Inc. operates in the biotechnology industry, focusing on the development of innovative medicines based on novel biological pathways. The company primarily targets interstitial lung diseases, with a particular focus on pulmonary sarcoidosis, through its product candidate efzofitimod.
Average Trading Volume: 4,929,313
Technical Sentiment Signal: Buy
Current Market Cap: $590.9M
See more data about ATYR stock on TipRanks’ Stock Analysis page.